Press releases

202420232022202120202019201820172016201520142013
Press release 2024/02/22
Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/02/15 Regulatory
MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2023

“The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over...

Read more
Press release 2024/01/31 Regulatory
Number of shares and votes in Medivir AB on 31 January 2024

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed...

Read more
Press release 2024/01/26 Regulatory
Medivir announces the outcome of the directed share issue which was announced on 22 January 2024

7,547,170 shares were issued, and all shares have been subscribed for by and allotted to Hallberg Management AB in accordance with...

Read more
Press release 2024/01/24
Medivir to present at the Redeye Fight Cancer Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/01/23
Medivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/01/22 Regulatory
Medivir carries out a directed share issue of approx. SEK 20 million

INSIDER INFORMATION: Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) (“Medivir” or the “Company”), a pharmaceutical company focused on developing innovative...

Read more
Press release 2024/01/17
Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium

Overall Response Rate (ORR) has increased to 25% (local review RECIST 1.1) Median time to progression continues to improve as data...

Read more
Press release 2024/01/15
Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit further supporting the continued development of fostrox

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/01/04
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more